No Data
No Data
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
Sutro Biopharma to Participate in Upcoming Investor Conferences
H.C. Wainwright Initiates Sutro Biopharma(STRO.US) With Hold Rating, Announces Target Price $2
Sutro Biopharma Analyst Ratings
Sutro Biopharma Announces Poster Presentations To Highlight Its Next-Generation Exatecan And Dual-Payload ADC Programs At Upcoming American Association for Cancer Research April 25-30 In Chicago, Illinois
Sutro Biopharma to Highlight Its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025